Pfizer eyes earlier Talzenna use after phase 3 prostate cancer win
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Pfizer is considering earlier use of its drug Talzenna after a phase 3 trial showed positive results in treating prostate cancer. The trial, known as TALAPRO-3, met its primary endpoint in a specific subset of patients. The outcome may impact Pfizer's oncology strategy and the drug's potential market position.
Full coverage
1
BioPharma Dive·Mar 192
Urology Times·Mar 193
Yahoo Finance·Mar 204
pharmaphorum·May 255Yahoo Finance·Mar 256
Fierce Pharma·Feb 297BioPharma Dive·Oct 178Fierce Pharma·Jun 13